Researchers from the Agency for Science, Technology and Research (A*STAR) and the National Healthcare Group (NHG) have jointly pioneered an innovative imaging technique combining Multispectral ...

A major international study, published this week in JAMA Psychiatry, has identified a powerful new brain-based biomarker for ...

Objectives Superb microvascular imaging (SMI) provides a more sensitive assessment of small vessels compared with power and colour Doppler ultrasonography (PDUS and CDUS). We aimed to investigate the ...

Willis Knighton Health in Shreveport, Louisiana, has opened a new nuclear oncology department, the first in the region. The ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

GE HealthCare completes acquisition of leading radiopharmaceutical company, Nihon Medi-Physics in Japan: Chicago Tuesday, April 1, 2025, 12:00 Hrs [IST] GE HealthCare Technologies ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.

UK MHRA approves trofolastat for diagnostic imaging of prostate cancer in men: United Kingdom Monday, March 31, 2025, 15:00 Hrs [IST] The Medicines and Healthcare products Regulat ...